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Abstract
Background: Azoles play an important role in the management of Aspergillus diseases. Azole resistance is an emerging
global problem in Aspergillus fumigatus, and may develop through patient therapy. In addition, an environmental route of
resistance development has been suggested through exposure to 14a-demethylase inhibitors (DMIs). The main resistance
mechanism associated with this putative fungicide-driven route is a combination of alterations in the Cyp51A-gene (TR34/
L98H). We investigated if TR34/L98H could have developed through exposure to DMIs.
Methods and Findings: Thirty-one compounds that have been authorized for use as fungicides, herbicides, herbicide
safeners and plant growth regulators in the Netherlands between 1970 and 2005, were investigated for cross-resistance to
medical triazoles. Furthermore, CYP51-protein homology modeling and molecule alignment studies were performed to
identify similarity in molecule structure and docking modes. Five triazole DMIs, propiconazole, bromuconazole,
tebuconazole, epoxiconazole and difenoconazole, showed very similar molecule structures to the medical triazoles and
adopted similar poses while docking the protein. These DMIs also showed the greatest cross-resistance and, importantly,
were authorized for use between 1990 and 1996, directly preceding the recovery of the first clinical TR34/L98H isolate in
1998. Through microsatellite genotyping of TR34/L98H isolates we were able to calculate that the first isolate would have
arisen in 1997, confirming the results of the abovementioned experiments. Finally, we performed induction experiments to
investigate if TR34/L98H could be induced under laboratory conditions. One isolate evolved from two copies of the tandem
repeat to three, indicating that fungicide pressure can indeed result in these genomic changes.
Conclusions: Our findings support a fungicide-driven route of TR34/L98H development in A. fumigatus. Similar molecule
structure characteristics of five triazole DMIs and the three medical triazoles appear the underlying mechanism of cross
resistance development. Our findings have major implications for the assessment of health risks associated with the use of
triazole DMIs.
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Introduction
Aspergillus fumigatus is the most frequent cause of Aspergillus
diseases in humans, which include allergic syndromes, aspergil-
loma and chronic or acute invasive aspergillosis. Antifungal agents
of the azole class play a prominent role in the management of
Aspergillus diseases. Three medical triazoles, itraconazole, vorico-
nazole and posaconazole, are clinically licensed for the prevention
and treatment of Aspergillus diseases [1]. It has become apparent
that A. fumigatus can develop resistance to the medical triazoles.
Azole resistance is commonly due to mutations in the cyp51A-gene,
encoding the target enzyme of antifungal azoles, and both
preclinical evidence and clinical experience suggests that reduced
in vitro susceptibility is associated with increased probability of
failure to azole therapy [2–4]. Azole resistance may develop
during azole therapy, which has been primarily reported in
patients with aspergilloma or other Aspergillus cavities that received
long-term azole therapy [5]. This route of resistance development
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31801
is characterized by recovery of azole-resistant A. fumigatus isolates
exclusively from patients receiving azole therapy and by a high
diversity of resistance mechanisms. Sometimes multiple resistance
mechanisms were found in different A. fumigatus colonies recovered
from a single patient [5]. The morphotype of A. fumigatus appears
to be important as the fungus commonly sporulates in cavities,
thus creating spores that harbor Cyp51A-mutations [7].
In the Netherlands, we observed azole resistance in A. fumigatus
isolates from azole-naı¨ve patients and in patients with invasive
aspergillosis, which is characterized by hyphal growth in the absence
of asexual reproduction. One explanation for this observation could
be that a second route of resistance development may exist through
environmental exposure of A. fumigatus to 14a-demethylase inhibitors
(DMIs) [4,6,7]. DMIs are abundantly used for crop protection against
phytopathogenic molds, for prevention of spoilage post harvest and for
preservation of materials. Evidence that supports such a route of
resistance development is the dominance of a single resistance
mechanism in over 90% of Dutch azole-resistant A. fumigatus isolates,
recovered from epidemiologically unrelated patients [6–8]. This
mechanism consists of a 34-bp insertion in the promoter region of the
cyp51A gene combined with a substitution at codon 98 of leucine to
histidine (TR34/L98H) [9]. TR34/L98H isolates were cultured from
patients that were azole-naı¨ve as well as those with previous azole
exposure, and were also recovered from the environment [10].
Genetic analysis showed clustering of clinical and environmental
TR34/L98H isolates compared to wild type controls [6,10]. TR34/
L98H isolates exhibit a multi-azole-resistant phenotype and azole-
resistant invasive aspergillosis was associated with a high mortality rate
of 88% [8,11]. In the Netherlands the first TR34/L98H isolate was
cultured in 1998 and since then the prevalence of clinical isolates
harboring TR34/L98H has increased over time [6,8].
Theoretically there are significant risks associated with the
environmental route of resistance development in fungi. First there
is the potential of migration of the resistance trait through sexual or
asexual reproduction. It has been shown for phytopathogens that
resistance mechanisms may develop locally and subsequently spread
across countries [12]. There are early indications that suggest that
migration is occurring in TR34/L98H as isolates harboring this
resistance mechanism have now been reported in other European
countries [13], and more recently in azole-resistant isolates in China
[14]. The other risk of the environmental route of resistance
development is the emergence of multiple resistance mechanisms
over time due to continued azole pressure. There are recent reports
that indicate that in addition to TR34/L98H other ‘environmental’
resistance mechanisms may be emerging [15,16].
Therefore, it is of great importance to explore the relationship
between the use of DMIs and the emergence of TR34/L98H in A.
fumigatus as this may enable effective measures to be taken that
prevent further increase of TR34/L98H isolates or of the
emergence of new resistance mechanisms. The aim of our
current research was to determine if route of TR34/L98H
development could have been fungicide driven. Our hypothesis
was that cross-resistance could develop if DMIs and medical
triazoles share similar molecule characteristics. This was
investigated through molecule alignment and docking studies
using a homology model of the CYP51A protein. Furthermore,
temporal relationships between DMI exposure and TR34/L98H
emergence were investigated. Finally, we investigated if the
TR34/L98H substitutions could be induced through DMI-
exposure under laboratory conditions. We were able to identify
five triazole DMIs that exhibit highly similar molecule charac-
teristics to medical triazoles and could have caused the
emergence of TR34/L98H in A. fumigatus.
Methods
Susceptibility testing
A collection of 25 clinical wild type A. fumigatus isolates, 25
clinical azole-resistant TR34/L98H isolates, 17 environmental wild
type isolates, and 13 environmental TR34/L98H isolates were
selected for investigation of the in vitro activity of fungicides. In
addition, two clinical isolates were included that have a tandem
repeat as underlying resistance mechanism similar to TR34/L98H:
one isolate harbored a 53-bp tandem repeat and the other a 46-bp
tandem repeat in combination with two substitutions in the
cyp51A-gene at codons 121 and 289. Finally, four isolates were
included that had a resistance mechanism that arose through azole
therapy, consisting of point mutations in the cyp51A-gene. All
isolates were previously identified by sequencing parts of the b-
tubulin gene and the calmodulin gene. Furthermore, the full
coding sequence and promoter region of the cyp51A-gene was
sequenced and microsatellite genotyping was performed [6].
Sequences were aligned with a reference cyp51A sequence
(GenBank accession no. AF338659) to identify mutations. All
isolates were stored in 10% glycerol at 280uC and subcultured on
Sabauroud slants at 37uC.
Between 1970 and 2005 33 compounds were authorized by the
Dutch Board for the Authorization of Plant Protection Products
and Biocides for use as fungicides, herbicides, herbicide safeners
and plant growth regulators, in The Netherlands. Of these 31 were
available for testing including: amitrole, benomyl, biteranol,
bromuconazole, carbendazim, cyazofamide, cyproconazole, dife-
noconazole, epoxiconazole, fenamidone, fenarimol, fenchlorazole-
ethyl, fuberidazole, imazamethabenz-methyl, imazilil, metcona-
zole, myclobutanil, nuarimol, paclobutrazole, penconazole, pro-
chloraz, propiconazole, prothioconazole, pyrimethanil, tebucona-
zole, thiabendazole, thiophanate-methyl, triadimefon, triademinol
I, triademinol II, triflumizole (Sigma Aldrich). The compounds
were dissolved in DMSO and autosterilized for 30 minutes at
room temperature. The minimal inhibiting concentration (MIC)
was determined using a microbroth dilution format according to
the CLSI M38-A2 reference method [17].
Docking studies
The structure of wild type CYP51A protein A. fumigatus was
derived from the crystal structure of human (PDB code: 3I3K) and
Mycobacterium tuberculosis (Mt) (PDB code: 1EA1) lanosterol 14a-
demethylase by homology modeling. Both proteins share 38% and
24% sequence identity with CYP51A of A. fumigatus, respectively
and contain ligands in the active site bound to heme. The three-
dimensional structures have been predicted by YASARA’s
homology modeling experiment (http://www.yasara.org). The
experiment consists from building four models based on different
alignment variants. The missing loops were modeled and
optimizations of structures ware performed. The model with the
best Z-score derived from the crystal structure of human lanosterol
14 a -demethylase was used for the presented studies.
In a recent publication by Fraczek et al. the Mycobacterium and
human structures were also both compared and confirmed the
choice for the human lanosterol 14 a -demethylase as the best
template for the A. fumigatus model [18]. The structures of tested
fungicides and medical triazoles (Table 1) were downloaded from
PubChem (http://pubchem.ncbi.nlm.nih.gov/). We used FlexX
for the docking experiment [19,20]. The coordination of ligands to
the iron atom of heme was treated as pharmacophore during the
docking procedure. The water molecule present in the active site
according to the crystal structure of 1EA1 was treated dynami-
cally. The program checked automatically whether the presence of
Fungicides and Azole Resistance in A. fumigatus
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the water molecule had favorable contribution to the docking pose
and only in such a case the water molecule was reported back,
otherwise it was neglected. The flexibility of hydrogen atoms of
Y107, Y121 and S297 was introduced to find an optimal docking
pose for the ligand. Docking the respective compounds back into
their crystal structure validated the docking procedure. The root
mean square deviation (RMSD) of the positions for fluconazole
(PDB code 1EA1) was 0.28 A˚ and for ketoconazole (PDB code
313K) 0.44 A˚. All the binding modes present in the crystal
structures were conserved [21,22].
Microsatellite genotyping
Microsatellite genotyping was used to determine the genetic
distances between TR34/L98H A. fumigatus isolates. A collection of
144 consecutive TR34/L98H isolates were used that originated
from two prospective surveillance studies that were performed in
the Netherlands. The first study included A. fumigatus isolates that
were collected in Dutch hospitals between 1994 and 2007. A total
of 1,912 A. fumigatus isolates were obtained from 1,219 patients
from the Radboud University Nijmegen Medical Center [6]. In
addition, 147 A. fumigatus isolates from 101 patients, from 28 other
medical centers in the Netherlands were collected [4,6]. The
second culture collection included 1,792 A. fumigatus isolates that
were collected from 1,192 patients in seven University Medical
Centers in the Netherlands between 2007 and 2009 [8]. Both
studies included an unselected collection of A. fumigatus isolates
(clinically relevant as well as colonizing isolates) and used agar
supplemented with itraconazole to detect for azole-resistance.
From six loci, consisting of three tri- and three tetranucleotide
repeats, fragments were amplified by using fluorescently labeled
primers. The sizes of the fragments were determined by addition
of the GeneScan LIZ[500] marker and subsequent analysis of the
fragments on the Applied Biosystems 3730 DNA analyzer.
Assignment of repeat numbers in each marker was determined
from the GeneScan data by using the Peak Scanner version 1.0
software (Applied Biosystems) [23]. By plotting the number of
observed new genotypes versus the time on a semi-logarithmic
scale, the year that the first new genotype emerged in The
Netherlands was calculated with a 95% confidence interval by
using the software package GraphPad Prism v5.00.
Induction experiments
Induction experiments were performed with the medical
triazole itraconazole (5 mg/l), the triazole DMIs bromuconazole
(8 mg/l), difenoconazole (8 mg/l), epoxiconazole (16 and 32 mg/
l), propiconazole (32 mg/l) and tebuconazole (8 mg/l) and all five
DMIs combined together in concentrations ranging between
0.063–4 mg/l of each DMI. Wild type isolate CM237 and
akuBKU80 as well as recombinant A. fumigatus isolates akuBKU80-
TR3 containing the 34-bp tandem repeat and akuBKU80-L98H2
containing the L98H substitution were used. A solution of 16106
of conidia was spread on a GYEP agar plate (glucose 2%, yeast
extract 0,3%, peptone 1% and agar 2%) containing one or a
combination of DMIs and subsequently passaged on GYEP agar
slants with the same concentration of DMI(s). Agar plates and
slants were incubated at 37uC, and isolate akuBKU80-TR3 was also
incubated at 25uC and 48uC. After 10 passages sequencing of the
cyp51A promoter and full coding gene was performed to detect
mutations.
Statistical analysis
In order to express differences in MIC50 between wild type and
TR34/L98H for the different compounds we first log transformed
the MIC50 data and then computed point biserial correlations as
correlation effect sizes (r) [24]. Values of r = 0 indicate similarity
between MIC50’s and values of r = 1 indicate the largest relative
dissimilarity. These correlation effect sizes cannot be computed in
cases where all samples have identical MIC50 values, such as with
compounds that show no in vitro activity against both wild type and
TR34/L98H isolates. In those cases the correlation effect size was
considered r = 0.
Results
Activity of fungicides against A. fumigatus
In the Netherlands 33 compounds have been authorized by the
Dutch Board for the Authorization of Plant Protection Products
and Biocides for use as fungicides, herbicides, herbicide safeners
and plant growth regulators, between 1970 and 2005, of these 19
were DMIs (Table 1; Figure 1; Figure 2A). We were able to obtain
31 of these compounds as dry powder and investigated the in vitro
activity against 38 TR34/L98H A. fumigatus isolates from clinical
and environmental origin and 42 wild type controls. In addition,
two azole-resistant isolates from environmental origin that harbor
a transcriptional enhancer as a resistance mechanism and four
isolates with point mutations in the cyp51A-gene that arose
through patient therapy were also tested (Table 2). Differences in
MIC50 between the wild type and TR34/L98H against all different
compounds were computed as correlation effect sizes (r). The
correlation coefficient is used as a measure of the size of an effect
with a value of 21 indicating a negative correlation between the
two variables, a value of 0 indicating no correlation and a value of
1 indicating a positive correlation. For the medical triazoles the
effect sizes were 0.99 for itraconazole, 0.82 for voriconazole and
0.85 for posaconazole representing a positive correlation of
dissimilarity between the MIC50’s of the wild type and TR34/
L98H isolates. Dissimilarity between the MIC50’s was found for 20
compounds, with the greatest differences (r.0.90) found for
propiconazole, difenoconazole, epoxiconazole (r = 0.96), bromu-
conazole (r = 0.95), metconazole (r = 0.94), imazalil (r = 0.94), and
tebuconazole (r = 0.93) (Figure 2B). These compounds were DMIs
from the triazole class, with the exception of imazalil. Isolates with
a 46 bp or 53 bp tandem repeat insertion showed similar
correlation effect sizes as TR34/L98H isolates (data not shown),
while isolates that had become resistant through patient azole
therapy generally showed lower r-values (Table 1) [25].
Molecule alignments and docking
We used a homology model of the A. fumigatus CYP-protein to
predict the preferred orientation of DMI-compounds to form a
stable complex with the 14a-lanosterol demethylase enzyme. A
crystal structure of the A. fumigatus CYP51A protein is not
available, therefore to see structural similarities in CYP51s for
azole inhibition we superimposed the fluconazole-bound Mycobac-
terium tuberculosis (Mt) structure (PDB code 1EA1), the ketocona-
zole-bound human structure (PDB code 313K) and ketoconazole-
bound A. fumigatus homology structure. Both fluconazole and
ketoconazole bind to the heme iron via the nitrogen of an azole
ring. The dihalogenated phenyl group, a common structural
moiety of ketoconazole and fluconazole, occupied the same spaces
at the active site of the heme molecule but interacts with the
binding pockets lined by different residues when the human
CYP51, the Mt CYP51 and the A. fumigatus CYP51 homology
model are aligned. In human and A. fumigatus CYP51, residues
Y145 and Y121, respectively formed van der Waals contacts with
the dichlorophenyl group of ketoconazole, whereas their side-
chain hydroxyl group made hydrogen bonds to the D-ring
propionate (C2H5COO
2) of the heme. Residue Y131 (PDB code
Fungicides and Azole Resistance in A. fumigatus
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Table 1. Antifungal susceptibilities of medical triazoles and compounds used as fungicide, herbicide, herbicide safener and plant
growth regulator.
Compound Target site of action
Chemical
group Year Median (Range) MIC50 (mg/ml)
Effect size
r
Clinical wild
type
Environment
wild type
Clinical TR/
L98H
Environment TR/
L98H
Itraconazole DeMethylation Inhibitors
SBI: Class I
triazoles 1991 0.125 (0.063–0.5) 0.25 (0.125–1) 32 (4–32) 32 (16–32) 0.99
Voriconazole DeMethylation Inhibitors
SBI: Class I
triazoles 2001 0.5 (0.5–2) 0.5 (0.5–4) 4 (2–8) 4 (1–32) 0.82
Posaconazole DeMethylation Inhibitors
SBI: Class I
triazoles 2006 0.031 (0.016–1) 0.063 (0.031–0.25) 0.5 (0.25–1) 0.5 (0.25–0.5) 0.85
Carbendazim Methyl Benzimidazole
Carbamates
benzimidazoles 1973 2 (1–16) 8 (2–16) 4 (1–32) 4 (1–32) 0.17
Fuberidazole Methyl Benzimidazole
Carbamates
benzimidazoles 1973 32 (32) 32 (32) 32 (32) 32 (32) 0*
Thiabendazole Methyl Benzimidazole
Carbamates
benzimidazoles 1973 32 (32) 32 (16–32) 32 (16–32) 32 (32) 0.10
Benomyl Methyl Benzimidazole
Carbamates
benzimidazoles 1975 2 (2–8) 4 (2–16) 8 (2–32) 4 (2–32) 0.31
Thiophanate-methyl Methyl Benzimidazole
Carbamates
thiophanates 1975 32 (32) 32 (32) 32 (32) 32 (16–32) 0.01
Cyazofamid Quinone inside Inhibitors cyanoimidazoles 2002 32 (32) 32 (32) 32 (32) 32 (32) 0*
Imazalil DeMethylation Inhibitors
SBI: Class I
imidazoles 1978 0.125 (0.125–0.5) 0.25 (0.125–0.5) 2 (1–8) 2 (2–8) 0.94
Prochloraz DeMethylation Inhibitors
SBI: Class I
imidazoles 1987 0.5 (0.25–0.5) 0.5 (0.125–0.5) 1 (1–32) 1 (1–32) 0.51
Triflumizole DeMethylation Inhibitors
SBI: Class I
imidazoles 1992 8 (4–16) 8 (4–32) 32 (8–32) 32 (32) 0.87
Imazamethabenz-
methyl
Acetohydroxyacid synthase
inhibitors
imidazolinone 1993 32 (32) 32 (32) 32 (16–32) 32 (32) 0.00
Fenarimol DeMethylation Inhibitors
SBI: Class I
pyrimidines 1983 8 (8–32) 8 (8–32) 32 (16–32) 32 (32) 0.07
Nuarimol DeMethylation Inhibitors
SBI: Class I
pyrimidines 1993 16 (8–32) 16 (8–32) 32 (16–32) 32 (32) 0.84
Pyrimethanil Methionine synthesis
inhibitors
anilino-
pyrimidines
1995 32 (32) 32 (32) 32 (32) 32 (32) 0*
Fenamidone Quinone outside Inhibitors imadazolinones 2005 32 (32) 32 (32) 32 (16–32) 32 (32) 0.00
Fenchlorazole Acetyl CoA Carboxylase
inhibitors
triazoles 1992 32 (32) 32 (32) 32 (32) 32 (32) 0*
Amitrole DeMethylation Inhibitors
SBI: Class I
triazoles 1970 32 (32) 32 (32) 32 (32) 32 (32) 0*
Triadimefon DeMethylation Inhibitors
SBI: Class I
triazoles 1980 32 (32) 32 (32) 32 (32) 32 (32) 0*
Bitertanol DeMethylation Inhibitors
SBI: Class I
triazoles 1983 4 (2–32) 16 (2–32) 32 (32) 32 (32) 0.71
Penconazole DeMethylation Inhibitors
SBI: Class I
triazoles 1986 32 (16–32) 32 (16–32) 32 (32) 32 (32) 0.36
Triadimenol I DeMethylation Inhibitors
SBI: Class I
triazoles 1988 32 (32) 32 (32) 32 (32) 32 (32) 0*
Triadimenol II DeMethylation Inhibitors
SBI: Class I
triazoles 1988 32 (32) 32 (32) 32 (32) 32 (32) 0*
Propiconazole DeMethylation Inhibitors
SBI: Class I
triazoles 1990 2 (2–4) 2 (2–8) 32 (16–32) 32 (16–32) 0.96
Cyproconazole DeMethylation Inhibitors
SBI: Class I
triazoles 1992 32 (8–32) 32 (2–32) 32 (16–32) 32 (16–32) 0.32
Tebuconazole DeMethylation Inhibitors
SBI: Class I
triazoles 1992 1 (1–4) 2 (1–8) 16 (8–16) 16 (8–16) 0.93
Myclobutanil DeMethylation Inhibitors
SBI: Class I
triazoles 1993 16 (8–32) 16 (4–32) 32 (32) 32 (32) 0.78
Difenoconazole DeMethylation Inhibitors SBI:
Class I
triazoles 1994 1 (1–2) 1 (1–4) 16 (8–32) 16 (8–16) 0.96
Fungicides and Azole Resistance in A. fumigatus
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313K) that is located in the B9 helix of the homology structure
(Y107) is invariant in the CYP51 family and involved in hydrogen-
bond formation with heme A-ring propionate in all three
structures. In the Mt structure, Y145-corresponding F89 is away
from the active site due to the conformational flexibility of the B–
C–helix region. Instead, R95 and R96 of Mt CYP51 are near the
heme and fluconazole difluorophenyl group (Figure 3). Thus,
ketoconazole could bind to Mt enzyme, utilizing the same space as
fluconazole for the dihalogenated phenyl ring, while the remainder
of ketoconazole would occupy the access channel observed in the
Table 1. Cont.
Compound Target site of action
Chemical
group Year Median (Range) MIC50 (mg/ml)
Effect size
r
Clinical wild
type
Environment
wild type
Clinical TR/
L98H
Environment TR/
L98H
Epoxiconazole DeMethylation Inhibitors SBI:
Class I
triazoles 1994 2 (2–8) 2 (2–16) 32 (32) 32 (32) 0.96
Bromuconazole DeMethylation Inhibitors SBI:
Class I
triazoles 1996 1 (1–4) 1 (1–4) 16 (8–32) 16 (16–32) 0.95
Paclobutrazole DeMethylation Inhibitors SBI:
Class I
triazoles 1997 16 (8–32) 16 (8–32) 32 (16–32) 32 (32) 0.82
Metconazole DeMethylation Inhibitors SBI:
Class I
triazoles 2005 0.25 (0.125–0.5) 0.25 (0.125–0.5) 2 (1–4) 1 (1–2) 0.94
Prothioconazole DeMethylation Inhibitors SBI:
Class I
triazoles 2005 8 (2–16) 8 (2–16) 16 (8–32) 16 (16–32) 0.71
*Cannot be computed because at least one of the variables is constant.
doi:10.1371/journal.pone.0031801.t001
Figure 1. Chemical structures of antifungal compounds. Three medical antifungal compounds and 31 compounds that were authorized by
the Dutch Board for the Authorization of Plant Protection Products and Biocides for use as fungicides, herbicides, herbicide safeners and plant growth
regulators. The compounds are presented according to structural group.
doi:10.1371/journal.pone.0031801.g001
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Figure 2. Overview of introduction of the 31 compounds by year and correlation effect sizes. A) Overview of compounds by year of
authorization by the Dutch Board for the Authorization of Plant Protection Products and Biocides (data from the Dutch Foundation for Phytofarmacy,
Nefyto). The five triazole DMIs that exhibited the most identical docking by molecule alignment are underlined in blue. B) Correlation effect sizes (r) of
compounds and medical triazoles comparing differences in the median MIC of wild type and TR34/L98H isolates. The fungicides are represented by
grey dots and those belonging to the DMIs by black. The medical triazoles are indicated in red, and the five triazole DMIs that exhibited the most
identical docking by molecule alignment are indicated in blue. *Correlation effect sizes could not be computed if in at least one of the two groups all
variables were constant. This was the case with compounds that showed no in vitro activity against both wild type and TR34/L98H A. fumigatus
isolates, and the correlation effect size was considered 0.
doi:10.1371/journal.pone.0031801.g002
Fungicides and Azole Resistance in A. fumigatus
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human enzyme although the channel would have to be open by
relocation of some of the side chains like F78 and M433 (grey
structure Figure 3). In the Mt structure, the hydroxyl group of
fluconazole made a water-mediated hydrogen bond to the heme
A-ring propionate. This water molecule is not observed in the
human structure because the cycle ether group of ketoconazole
filled in the space of water. In addition, in Mt and A. fumigatus
CYP51s an invariant H259/H296 residue from helix I is pointed
into the active site, whereas the confirmation of the corresponding
H314 in human CYP51 prevents its interaction with the
inhibitors. The itraconazole, posaconazole and voriconazole
molecules were docked into the A. fumigatus homology structure.
They showed the same binding pattern as described for the crystal
structures and were able to align to the presented poses of
fluconazole (representative of voriconazole) and ketoconazole
(representative of itraconazole and posaconazole). The compounds
from the groups of imidazoles, pyrimidines and triazoles adopted
similar poses upon docking in the active site of the A. fumigatus as
those observed for the medical triazoles. The largest dissimilarities
were in the cases of compounds that lack a phenyl group next to
Table 2. Activity of medical triazoles and five DMIs against clinical and environmental A. fumigatus isolates with different cyp51A-
mediated resistance mechanisms.
Resistance mechanism Median MIC (mg/l)
cyp51A gene* # isolates Medical triazoles
& DMIs
Promoter region Coding region ITC VCZ POS Bromuconazole Difenoconazole Epoxiconazole Propiconazole Tebuconazole
– – 42 0.125 0.5 0.063 1 1 2 2 1
34 bp TR L98H 38 .16 4 0.5 16 16 .16 .16 16
46 bp TR Y121F, T289A 1 2 .16 0.5 .16 .16 .16 .16 16
53 bp TR – 1 .16 16 0.25 16 .16 .16 .16 16
– G54W 1 .16 0.25 .16 0.5 0.125 0.5 0.5 0.5
– G54E 1 .16 0.25 1 0.25 0.25 0.5 0.5 0.5
– M220I 1 .16 1 0.5 4 4 16 16 4
– M220V 1 .16 2 1 4 2 8 4 4
*TR, tandem repeat.
&ITC, itraconazole; VCZ, voriconazole; POS, posaconazole.
doi:10.1371/journal.pone.0031801.t002
Figure 3. 3D representation of three aligned structures of CYP51 with the ligands in their active site, constructed by using the
Yasara software. In green human CYP51 bound with ketoconazole from PDB: 3I3K; in gray Mt bound with fluconazole from PDB: 1EA1; in cyan A.
fumigatus bound with ketoconazole from the homology model. The ligands are represented in balls and sticks, only the residues important for
binding a particular ligand are depicted in the picture and represented in sticks. Numbering of the residues corresponds with their colors to the
models.
doi:10.1371/journal.pone.0031801.g003
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the 5- or 6-member aromatic ring that coordinates to the iron
center. We performed a flexible alignment of the compounds on
the structure of voriconazole in order to find the most similar
compounds. The pharmacophores used as a filter for the
alignment that consist of 5/6-member aromatic ring containing
at least one nitrogen atom, a hydrogen-bond donor or acceptor
and the aromatic functional group (Figure 4). The structures
classified to groups of benzimidazoles, cyaninoimidazoles together
with prochloraz, imazamethabenz from imidazolinone, and
pyrimethanil from pyrimidines and fenamidone and amitrole
from triazoles were filtered out from the set of the ligands as not
similar to the voriconazole molecule. The remaining 20 of 31
structures were considered to be similar to the medical triazoles.
We focused our analysis of the docking poses on the compounds
that satisfied the given pharmacophores for alignment.
Docking poses of fungicides similar to medical triazoles
The triazole DMIs that have three nitrogen atoms in the
aromatic ring coordinated to the iron atom of heme made a
hydrogen bond contact to residue S297, present in the active site
of the A. fumigatus CYP51 homology model. Residue H296, also
present in the active site, interacted with most of the fungicides
with the exception of imazalil, triflumizole, fenarimol, nuarimol,
penconazole, metconazole that instead interacted with a bridging
water molecule. Propiconazole, myclobutanil, difenoconazole lack
any interaction with residue H296 or a bridging water molecule.
Most of the DMIs share the core structure with medical triazoles
and due to this similarity they adopt much the same poses in the
active site of A. fumigatus as the medical triazoles. Propiconazole
and bromuconazole exhibit the most alike poses with the core
structure being the most similar to itraconazole and posaconazole
(Figure 5A). Tebuconazole and epoxiconazole also adopted the
most alike poses being most similar to voriconazole, except they
interacted with residue H296 in the active site (Figure 5B). The
analysis of the top three poses proposed by the docking program
showed that these compounds were able to adopt also poses where
they interacted with a bridging water molecule instead of H296.
This makes the binding modes of propiconazole, bromuconazole,
tebuconazole and epoxiconazole most identical to those repre-
sented by the medical triazoles. Difenoconazole (Table 1) was
different in structure from the rest of the cross-resistant DMIs.
Instead of one aromatic ring (Figure 5A and 4B) it has a biphenyl
moiety, upon docking this part was placed into the access channel
where the long tail of medical azoles is normally located.
The above mentioned five triazole DMIs were also among the
compounds with the highest r-value and showed complete loss of in
vitro activity against A. fumigatus isolates harboring TR34/L98H
(Figure 2B, Table 1). Moreover, these five DMIs were authorized
for use in the Netherlands between 1990 and 1996 (Figure 2A),
which preceded the first known isolation of a clinical TR34/L98H
isolate in 1998 [6]. Imazalil and metconazole also showed a high
correlation effect size (Figure 2A), but, unlike the five above-
mentioned triazole DMIs, retained in vitro activity against TR34/
L98H isolates (median MIC of 2 mg/l) (Table 1). Docking studies
and molecule alignments showed that imazalil and metconazole
Figure 4. Two-dimensional structure of voriconazole with
indicated pharmacophores that were used to align and filter
the 31 compounds (Table 1). The figure was constructed by using
Marvin Sketcher form ChemAxon (www.chemaxon.com).
doi:10.1371/journal.pone.0031801.g004
Figure 5. Analysis of most modes binding modes compared to the medical triazoles. A) Binding modes of propiconazole. This fungicide
exhibits the most similar binding modes compared to the medical triazoles located in the active site of human and A. fumigatus CYP51. B) Binding
modes of tebuconazole. This fungicide exhibits the most similar binding modes compared to the medical triazoles located in the active site of Mt
CYP51. The main difference between A and B is the interactions with residue H296 in the active site, which is lacking in A.
doi:10.1371/journal.pone.0031801.g005
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were less similar to the medical triazoles and therefore less likely to
have caused the emergence of TR34/L98H in A. fumigatus.
Microsatellite genotyping
A. fumigatus isolates from two Dutch surveillance studies were
used to investigate the evolution of TR34/L98H genotypes over
time [6,8]. The collections were obtained prospectively over a 16
year period and included 3,847 isolates from 2,512 patients. All
isolates were screened for azole resistance by subculture on agar
supplemented with itraconazole. The collections included 144
consecutive TR34/L98H isolates which were genetically charac-
terized by short tandem repeat genotyping [23]. By plotting the
number of observed new genotypes versus time on a semi-
logarithmic scale, we calculated a rate of change of 1.3760.05
genotype-1.year-1. Using the rate of change to calculate the year
of first emergence of TR34/L98H, indicated that TR34/L98H had
developed in the year 1997 (95% CI: 1993.7–1999.7) (Figure 6).
Induction of TR34/L98H
We investigated if the TR34/L98H substitutions could be
induced during exposure to DMIs under laboratory conditions. A
wild type A. fumigatus isolate and recombinants containing either
the 34-bp insertion or the L98H substitution were exposed to
itraconazole, bromuconazole, difenoconazole, epoxiconazole,
propiconazole, tebuconazole or a mixture of these DMIs. The
induction experiments generally resulted in a resistant phenotype
within three passages. In three out of twelve clones of A. fumigatus
cultured under itraconazole pressure, cyp51A-substitutions G138C
or P216L were detected. These substitutions have been reported in
patients who developed azole-resistant Aspergillus disease during
itraconazole therapy [5]. TR34/L98H was not found in any of the
clones that were exposed to itraconazole, single DMI compounds
or to a mixture of DMIs. However, following exposure of the A.
fumigatus conidia containing the 34-bp insertion in the cyp51A-gene
promoter to 8 mg/l of tebuconazole resulted in one clone in which
after three passages a triplicate of the 34 bp sequence was detected
in the promoter region.
Discussion
Although the hypothesis of a fungicide-driven route of azole
resistance development in A. fumigatus is controversial [26], we
provide evidence that such a route may exist. Five triazole DMIs
were identified that exhibited very similar molecule characteristics
to the medical triazoles, resulting in the most identical binding
modes and the greatest level of cross-resistance. These five DMIs
were authorized for use between 1990 and 1996, which was in
keeping with our calculated date of origin of TR34/L98H based on
microsatellite typing, and precedes the first clinical TR34/L98H
isolate in 1998. Continued triazole DMI pressure and lack of an
apparent fitness cost in TR34/L98H isolates are probably
important factors that have facilitated the ability of TR34/L98H
to sustain in the field in competition with wild type isolates.
Although the relation between the use of antimicrobial agents
outside human medicine and the development of resistance to
clinically used compounds has been shown for bacteria, we show
for the first time evidence that the same principle may occur in
molds. Culture-based surveillance studies increasingly report
TR34/L98H in clinical and environmental isolates in Europe
and, most recently, in China [14]. Moreover, there is very recent
evidence that two new ‘environmental’ azole resistance mecha-
nisms have emerged in A. fumigatus in the Netherlands, of which
one has rapidly migrated across the country similar to TR34/
L98H [27]. However, surveillance studies based on positive
cultures may underestimate the prevalence of resistance. Detection
of azole resistance mechanisms directly in clinical specimens from
patients with chronic lung diseases showed that in culture-
Figure 6. The evolution of new microsatellite genotypes over time based on short tandem repeat typing of 144 TR34/L98H A.
fumigatus isolates, cultured between 1998 and 2009 in the Netherlands. By plotting the number of observed new genotypes versus time on
a semi-logarithmic scale, a rate of change of 1.3760.05 genotype-1.year-1 was calculated. As the first TR34/L98H isolate was cultured in 1998, the rate
of change indicates that the first strain would have emerged around 1997 (95% CI: 1993.7–1999.7). This analysis also indicates that TR34/L98H had
developed from a single ancestor.
doi:10.1371/journal.pone.0031801.g006
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negative, PCR-positive samples cyp51A-mutations were detectable
in as many as 55.1% of respiratory samples [28]. These
observations indicate that we are just beginning to understand
the scale of the problem, but it suggests that azole resistance in A.
fumigatus has become a public health problem and threatens an
increasing population of (immunocompromised) patients.
Our study was limited by the fact that we were unable to induce
the full TR34/L98H resistance mechanism during DMI-pressure
under laboratory conditions, using an isolate that is deficient in
DNA break repair. Previously, microsatellite genotyping showed
shorter genetic distances for TR34/L98H isolates compared with
wild type isolates [10], which suggests that TR34/L98H isolates
may have originated from a common ancestor. If this would be the
case, the development of TR34/L98H would be extremely
infrequent in the environment and would explain why we were
unable to induce TR34/L98H under laboratory conditions.
However, this may point to other reasons for the emergence of
TR34/L98H. TR34/L98H isolates may have other properties,
such as increased fitness or virulence, or high sporulation efficacy,
that have made isolates harboring TR34/L98H more successful in
the field than wild type A. fumigatus. However, at present there is no
evidence that supports increased virulence in TR34/L98H isolates.
Animal studies indicate that the virulence of TR34/L98H is similar
to that of wild type isolates, although only one TR34/L98H isolate
was used [3]. An alternative explanation for our inability to induce
TR34/L98H could be that this resistance mechanism developed
through sexual or parasexual reproduction rather than asexual
reproduction, which was not tested in the laboratory. However, we
did observe one isolate in which two copies of the tandem repeat
evolved into three, supporting the role of DMIs in inducing
genomic changes in cyp51A of A. fumigatus. Another limiting factor
of our studies was the lack of sequence-based evolutionary analysis.
In A. fumigatus no genes have been described that are suitable for
this type of analysis and therefore we used microsatellite data.
The relation between the use of the triazole DMIs and cross-
resistance to medical triazoles in A. fumigatus has major
implications for the assessment of health risks associated with the
use of DMIs. Molecule structure similarity and activity of triazole
DMIs against A. fumigatus appear to be the key features that cause
cross-resistance to medical triazoles. Further research should be
aimed at understanding the conditions under which resistance
mechanisms develop in the environment and which Aspergillus
morphotype is most prone to develop resistance mechanisms.
Reversal of resistance development may be achievable by
restriction of certain triazole DMIs, but laboratory population
studies and genetic mapping would be required to predict the
impact of changes in DMI-pressure. In addition, there is limited
insight in the use of fungicides for agricultural and non-agricultural
applications.
The continued use of DMIs with activity against opportunistic
human fungal pathogens is a risk for the management of fungal
diseases caused by these pathogens. The number of classes of drugs
available for treating non-invasive and invasive fungal diseases is
limited and the triazoles are the only class of antifungal agents that
can be administered orally. A fungicide-driven route of resistance
development in TR34/L98H could indicate that such mechanisms
may also occur in other Aspergillus species or other opportunistic
fungi. It is therefore of great importance to perform above-
mentioned research as it may allow the implementation of
evidence-based strategies aimed at elimination of the fungicide-
driven route of azole resistance development in opportunistic
fungi.
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